Oncopeptides AB (publ)
OTC: ONPPF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sofia Heigis
- Employees
- 80
- Headquarters
- Stockholm, Sweden
- IPO year
- 2020
- Market cap
- $56.0M
- Website
- https://www.oncopeptides.com/sv
Loading ONPPF…
Loading profile data…Frequently asked questions about ONPPF
What does Oncopeptides AB (publ) (ONPPF) do?
Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to...
Where does ONPPF trade?
Oncopeptides AB (publ) (ONPPF) trades on the Other OTC.
What sector is ONPPF in?
Oncopeptides AB (publ) (ONPPF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oncopeptides AB (publ)?
Sofia Heigis is the chief executive officer of Oncopeptides AB (publ) (ONPPF).
Where is Oncopeptides AB (publ) headquartered?
Oncopeptides AB (publ) is headquartered in Sweden.
Does ONPPF pay a dividend?
Oncopeptides AB (publ) (ONPPF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONPPF go public?
Oncopeptides AB (publ) (ONPPF) completed its initial public offering in 2020.